Stockscreener 앱 받기
13.56
2.57%
0.34
시간 외 거래:
13.48
-0.08
-0.59%
전일 마감가:
$13.22
열려 있는:
$13.28
하루 거래량:
3,563
Relative Volume:
0.97
시가총액:
$N/A
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+1.27%
1개월 성능:
-10.91%
6개월 성능:
-9.75%
1년 성능:
+29.20%
1일 변동 폭
$13.28
$13.70
1주일 범위
$13.09
$13.70
52주 변동 폭
$10.49
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
CNCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| CNCR | 13.56 | 0 | 0 | 0 | 0 | 0.00 |
| VTI | 296.51 | 417.53B | 0 | 0 | 0 | 0.00 |
| SPY | 595.51 | 372.57B | 0 | 0 | 0 | 0.00 |
| IVV | 598.45 | 253.41B | 0 | 0 | 0 | 0.00 |
| VB | 257.73 | 160.59B | 0 | 0 | 0 | 0.00 |
| QQQ | 505.79 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf 주식(CNCR)의 최신 뉴스
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
Disruptive Theme of the Week – Breakthroughs in Medicine - ETF Trends
CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
Charted: Cancer Survival Rates Over Time - Visual Capitalist
Range Cancer Therapeutics - TBR News Media
How this award-winning TV host is setting the stage to help protect her health - TBR News Media
Investment fund pledges revenues in cancer research partnership with CSHL - TBR News Media
(CNCR) Trading Signals - Stock Traders Daily
At a Glance: Nov. 6 - Crain's New York Business
7 Best-Performing Biotech ETFs for November 2024 - NerdWallet
(CNCR) Trading Report - Stock Traders Daily
The 5 Best Biotech ETFs of 2024 - TradingView
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Science & Technology - TBR News Media
(CNCR) Investment Report - Stock Traders Daily
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
(CNCR) Investment Analysis - Stock Traders Daily
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
Trackinsight ETF data from 23rd to 27th September, 2024 - ETF Express
(CNCR) Investment Analysis and Advice - Stock Traders Daily
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Roundhill Investments Surpasses $2 Billion AUM Milestone – Company Announcement - Financial Times
5 ETFs That Led the Rebound on Monday - Yahoo Finance
IPO Roundup: Bicara Therapeutics, Kairos Pharma and more (NYSEARCA:IPO) - Seeking Alpha
Trading (CNCR) With Integrated Risk Controls - Stock Traders Daily
Cellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS) - Seeking Alpha
Best-Performing ETF Areas of Past Week - MSN
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology (TCRX) - Seeking Alpha
Why It May Be 'Just Right' to Invest in Cancer Therapeutics Development Stocks Now - Nasdaq
3 Top-Ranked ETFs Under $20 for Your Portfolio - MSN
Invest in Hope, Invest in Life - Nasdaq
5 Top-Ranked ETFs to Buy at a Bargain - Yahoo Finance
Wall Street indexes rise after strong jobs data - Yahoo News Canada
VIXY Jumped 7.3% Last Week - Yahoo Finance
SPY Led Inflows Last Week as Leveraged Funds Surged - etf.com
Best ETFs of Last Week - Yahoo Finance
US stocks waver, extending tech-led selloff - Yahoo Singapore News
Time for Healthcare ETFs? - Yahoo Finance
TSLA-related ETFs among top performing ETFs on a 4-week performance base last week - MSN
5 Top ETFs of Last Week - Yahoo Finance
US consumer inflation eases more than expected - Yahoo Singapore News
How the (CNCR) price action is used to our Advantage - Stock Traders Daily
GordonMD® Global Investments Portfolio Company, Radionetics Oncology, Announced Strategic Agreement with Lilly - Yahoo Finance
Range Cancer Therapeutics Etf (CNCR) 재무 분석
Range Cancer Therapeutics Etf (CNCR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.73%
자본화:
|
볼륨(24시간):